SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that its non-invasive organ transplant surveillance solutions are being used to help monitor post-operative graft health in the world’s first successful heart xenotransplantation. A genetically modified pig heart was successfully transplanted into a patient at the University of Maryland Medical Center on January 7, 2022.
{iframe}https://www.globenewswire.com/news-release/2022/02/22/2389123/31386/en/CareDx-Leads-the-Way-in-Xenotransplant-Organ-Surveillance-in-Monitoring-World-s-First-Successful-Living-Xenotransplantation.html{/iframe}